BMRN
Biomarin·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 4
Bearish signal 2
Consensus Rating "Buy"
Ample Liquidity
High Gross Profit Margin
Significant Net Income Decline
EPS Beats Expectation
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About BMRN
Biomarin Pharmaceutical Inc.
A global biotech company that develops therapies for rare diseases and medical conditions
770 Lindaro Street, San Rafael, California 94901
--
Biomarin Pharmaceutical Inc., was incorporated in Delaware in October 1996 and commenced operations on March 21, 1997. The company is a global biotechnology company that transforms the promise of genetic discovery into drugs that have a profound impact on the lives of every patient. T. BioMarin selects product candidates for diseases and conditions representing significant unmet medical needs that have a good biological understanding and provide opportunities to be the first to market or offer advantages over existing products. The company's product portfolio consists of four approved products and multiple research candidates.
Earnings Call
Q1/2025
Estimate EPS0.95
Actual EPS1.13
Estimate Revenue738.66M
Actual Revenue745.00M
BioMarin's Q1 2025 Earnings Call: Unpacking Contradictions in Growth Prospects and Strategic Direction
May 02,2025 07:32
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS1.01
Actual EPS1.44
Estimate Revenue761.66M
Actual Revenue825.00M
BioMarin's Q2 2025: Revenue Growth and Strategic Contradictions Unveiled
Aug 04,2025 11:16
Earnings Decrypt
Earnings Decrypt
Q3/2025
Estimate EPS0.32
Actual EPS0.12
Estimate Revenue780.22M
Actual Revenue776.00M
BioMarin's 2025 Q3 Earnings Call: Contradictions Emerge on VOXZOGO Sales, 2027 Guidance, Business Development Strategy, and BMN 333 Efficacy
Oct 27,2025 09:36
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
BMRN has released its 2025 Q3 earnings. EPS was reported at 0.12, versus the expected 0.32, missing expectations. The chart below visualizes how BMRN has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
BMRN has released its 2025 Q3 earnings report, with revenue of 776.13M, reflecting a YoY change of 4.08%, and net profit of -30.74M, showing a YoY change of -128.98%. The Sankey diagram below clearly presents BMRN's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
